Cardiac AgeingNCT04501562
TO-ChERIsH: Trajectory of Cardiovascular Ageing, Its Determinants and Impact on Health
An observational study of Cardiac Ageing, run by National Heart Centre Singapore at 1 site in Singapore.
Trial summary
Specific Aim 1: To determine longitudinal changes in CV ageing (changes in CV imaging) over time. Hypothesis: There are differences in rates of CV ageing over time. Specific Aim 2: To study determinants of CV ageing To assess how biological pathways affect CV ageing by studying the relationships between biological… Read more about this study
- Who is it for?
- Ages 21 to 100 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiac Ageing
- What is being tested?
- Examinations, Cardiovascular Tests and Bio-specimen collection
- How many people
- 500 participants
- Where
- 1 siteSingapore
- Study dates
- 13 May 2019to Dec 2049
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 100 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants are recruited through population based studies (Singhealth IRB 2018/3173).
Who may be able to join
- >= 21 years old
Who cannot join
- Unable to provide written informed consent to participate in the study
Trial locations and contacts
1 site in 1 country.
Singapore1 site
National Heart Centre Singapore
Singapore, Singapore, 169609
About this study
Specific Aim 1: To determine longitudinal changes in CV ageing (changes in CV imaging) over time.
Hypothesis: There are differences in rates of CV ageing over time.
Read more
Specific Aim 2: To study determinants of CV ageing To assess how biological pathways affect CV ageing by studying the relationships between biological signatures measured in longitudinal biospecimens are associated with CV ageing.
Hypothesis: Antecedent biological markers are associated with progression of CV ageing.
Specific Aim 3: To determine the impact of CV ageing progression on the development of clinical CVD and the overall physical, cognitive and functional health of the elderly.
Hypothesis: Those with stable CV imaging phenotypes have lower incidence of clinical CVD and also better overall health in ageing, compared to those with rapid deterioration (unhealthy CV ageing).
Read the detailed description
In Singapore, elderly residents aged 65 years and above make up 10.5% of our population and this is expected to double in 2030 (Singapore Department of Statistics, Ministry of Manpower, Registry of Birth and Deaths, September 2014). Cardiovascular diseases account for the majority of disability-adjusted life years by broad cause group, accounting for 20% of 399,675 life years lost due to mortality and ill-health in 2010 (Source: Estimates from the Singapore Burden of Disease Study 2010).
While chronological ageing is inevitable, a clear understanding is needed as to how ageing becomes a critical risk component of CVD for some individuals, and the mechanisms through which ageing results in such a vulnerable phenotype that leads towards clinical CVD. Following that, clinical tools and clinical guidelines to reduce cardiovascular disease and other health burdens contributed by ageing may be formulated. Such strategies may potentially reduce burdens and cost of healthcare provision to the ageing population.
Our proposal will generate data that identifies functional and structural changes in the cardiovascular system that occur in during ageing. Using a longitudinal design, this research will provide high quality evidence that distinguishes healthy from unhealthy cardiovascular ageing, and reveal determinants and impact of CV ageing over time on CVD and associated health outcomes.
- Conditions
- Cardiac Ageing
- Being tested
- Examinations, Cardiovascular Tests, Bio-specimen collection, Clinical/health outcome collection
- Keywords
- Echocardiogram, MRI/MRS
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExaminationsOther
Participants will undergo focused examinations that include measurement of height, weight, waist circumference, body composition analysis, baseline data collection and blood pressure examinations. Resting electrocardiography will be performed to ascertain sinus rhythm.
Cardiovascular TestsOther
Specific quantitative cardiac ageing-related outcome parameters will be examined by multimodal techniques including two-dimensional transthoracic echocardiogram, and/or non-contrast magnetic resonance imaging/magnetic resonance spectroscopy.
Bio-specimen collectionOther
Bio-specimens collected will include fresh blood, urine and/or stool specimens.
Clinical/health outcome collectionOther
Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.
| Study group | Role | What they receive |
|---|---|---|
| Subject | Not described Receives: Other: Examinations; Other: Cardiovascular Tests; Other: Bio-specimen collection; Other: Clinical/health outcome collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
To identifies functional and structural changes in the cardiovascular system that occur in during ageing.
Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.
Measured: 5 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2020
- Study start13 May 2019
- Primary completionDec 2049 (estimated)
- Study completionDec 2049 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac AgeingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Heart Centre Singapore
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Angela Koh, M.D., Principal investigator, National Heart Centre Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04501562
- Sponsor's protocol ID
- 2019/2252
- Status last verified
- Apr 2025
- First submitted
- 2 Aug 2020
- Last updated
- 5 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- TO-ChERIsH: Trajectory of Cardiovascular Ageing, Its Determinants and Impact on Health
- ClinicalTrials.gov ID
- NCT04501562
- Acronym / sponsor ID
- 2019/2252
- Conditions
- Cardiac Ageing
- Keywords
- Echocardiogram, MRI/MRS
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- National Heart Centre SingaporeUniversity, hospital or other
- Study start
- 13 May 2019 (actual)
- Primary completion
- Dec 2049 (estimated)
- Study completion
- Dec 2049 (estimated)
- First posted
- 6 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Specific Aim 1: To determine longitudinal changes in CV ageing (changes in CV imaging) over time.
Hypothesis: There are differences in rates of CV ageing over time.
Specific Aim 2: To study determinants of CV ageing To assess how biological pathways affect CV ageing by studying the relationships between biological signatures measured in longitudinal biospecimens are associated with CV ageing.
Hypothesis: Antecedent biological markers are associated with progression of CV ageing.
Specific Aim 3: To determine the impact of CV ageing progression on the development of clinical CVD and the overall physical, cognitive and functional health of the elderly.
Hypothesis: Those with stable CV imaging phenotypes have lower incidence of clinical CVD and also better overall health in ageing, compared to those with rapid deterioration (unhealthy CV ageing).
Detailed description
In Singapore, elderly residents aged 65 years and above make up 10.5% of our population and this is expected to double in 2030 (Singapore Department of Statistics, Ministry of Manpower, Registry of Birth and Deaths, September 2014). Cardiovascular diseases account for the majority of disability-adjusted life years by broad cause group, accounting for 20% of 399,675 life years lost due to mortality and ill-health in 2010 (Source: Estimates from the Singapore Burden of Disease Study 2010).
While chronological ageing is inevitable, a clear understanding is needed as to how ageing becomes a critical risk component of CVD for some individuals, and the mechanisms through which ageing results in such a vulnerable phenotype that leads towards clinical CVD. Following that, clinical tools and clinical guidelines to reduce cardiovascular disease and other health burdens contributed by ageing may be formulated. Such strategies may potentially reduce burdens and cost of healthcare provision to the ageing population.
Our proposal will generate data that identifies functional and structural changes in the cardiovascular system that occur in during ageing. Using a longitudinal design, this research will provide high quality evidence that distinguishes healthy from unhealthy cardiovascular ageing, and reveal determinants and impact of CV ageing over time on CVD and associated health outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Subject | – | Other: Examinations, Other: Cardiovascular Tests, Other: Bio-specimen collection, Other: Clinical/health outcome collection |
Who may qualify
- Ages
- 21 to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants are recruited through population based studies (Singhealth IRB 2018/3173).
Key inclusion criteria (1 listed)
- >= 21 years old
Key exclusion criteria (1 listed)
- Unable to provide written informed consent to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ExaminationsParticipants will undergo focused examinations that include measurement of height, weight, waist circumference, body composition analysis, baseline data collection and blood pressure examinations. Resting electrocardiography will be performed to ascertain sinus rhythm. | Other | Subject |
| Cardiovascular TestsSpecific quantitative cardiac ageing-related outcome parameters will be examined by multimodal techniques including two-dimensional transthoracic echocardiogram, and/or non-contrast magnetic resonance imaging/magnetic resonance spectroscopy. | Other | Subject |
| Bio-specimen collectionBio-specimens collected will include fresh blood, urine and/or stool specimens. | Other | Subject |
| Clinical/health outcome collectionHealth status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades. | Other | Subject |
Primary outcome
To identifies functional and structural changes in the cardiovascular system that occur in during ageing.
Time frame: 5 Years
Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Cardiac Ageing
Recruiting
Auricular Vagus Nerve Stimulation Mechanisms for HIV-Associated Peripheral Neuropathy
HIV Associated Polyneuropathy
Active, not recruitingPhase 2
Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]
Aging
Not yet recruitingObservational study
CHIP in Health and Disease
Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential
RecruitingObservational study
Multimodal Cardiovascular and Hepatic Population Imaging
Healthy Volunteers, Imaging Evaluation
Not yet recruiting
Community Physical Exercise Program in Chronic Disease
Osteoarthritis Pain, Myocardial Infarction (MI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Angela Koh, M.D. principal investigator
National Heart Centre Singapore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiac Ageing, run by National Heart Centre Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To identifies functional and structural changes in the cardiovascular system that occur in during ageing. (time frame: 5 Years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2025.